|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.03.26 - 17:48
|
Why Cardinal Health May Be a Best Buy for the Coming Stagflation (24/7 Wall St.)
|
|
|
This morning's jobs report landed hard. Nonfarm payrolls plunged by 92,000 jobs, shattering expectations of a 55,000 gain. Unemployment climbed to 4.4%, while average hourly earnings jumped 0.4% month-over-month — well above the 0.3% consensus. The Federal Reserve is now caught in a classic stagflation trap: slashing rates risks reigniting inflation, yet raising them is ... Why Cardinal Health May Be a Best Buy for the Coming Stagflation
The post Why Cardinal Health May Be a Best Buy for the Coming Stagflation appeared first on 24/7 Wall St.....
|
|
|
|
|
05.03.26 - 23:12
|
VDyne Appoints Mike Buck as Chairman and CEO to Lead Next Phase of its TTVR Program (Business Wire)
|
|
|
MAPLE GROVE, Minn.--(BUSINESS WIRE)--VDyne Inc. (“VDyne”), a privately held medical device company developing a transcatheter tricuspid valve replacement (TTVR) system to treat tricuspid regurgitation, today announced the appointment of Mike Buck as Chairman and Chief Executive Officer.
Mr. Buck brings more than 30 years of leadership experience in cardiovascular medical technology. Most recently, he served as Chief Executive Officer of Verge Medical and previously was Founder and Chief Executive Officer of TRUVIC Medical (acquired by Imperative Care). Earlier in his career, he served as President of Cardinal Health's Medical Products Division and held senior leadership roles at Abbott, including Corporate Vice President and global commercial leader for Abbott's Vascular business, as well as leading Abbott's global Licensing and Acquisitions function.
VDyne has conducted clinical studies across 15 countries, with more than 100 successful TTVR procedures to date. The Company has received FDA Breakth...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
